DDInter1652 DDInter1965
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Zinc gluconate is a zinc salt of gluconic acid comprised of two gluconic acid molecules for each zinc cation (2+). Zinc gluconate is a generally recognized as safe (GRAS) substance by FDA . It is available as a trace mineral supplement and over the counter as a lozenge form for a reduced duration of common colds and with decreased symptom severity. Although it has been nasally administered for treating the common cold, this route of administration has been associated with some cases of anosmia , , , . Studies show that zinc may be better absorbed in humans in the gluconate form , , however, results from other studies may vary.[A27280, L2082] Interestingly, zinc supplementation has become a critical intervention for treating diarrheal episodes in children. Studies suggest that administration of zinc along with new low osmolarity oral rehydration solutions/salts (oral rehydration solution), may reduce both the duration and severity of diarrheal episodes for up to 12 weeks . More information about Zinc (in its natural form) is available at .
Zinc gluconate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mycophenolic acid
Zinc gluconate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Satralizumab
Zinc gluconate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gatifloxacin
Zinc gluconate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Baloxavir marboxil
Zinc gluconate {u} may lead to a major life threatening interaction when taken with {v} Raltegravir
Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Mycophenolic acid
Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Satralizumab
Zinc gluconate may cause a moderate interaction that could exacerbate diseases when taken with Gatifloxacin
Zinc gluconate may cause a moderate interaction that could exacerbate diseases when taken with Baloxavir marboxil
Zinc gluconate may lead to a major life threatening interaction when taken with Raltegravir